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Abstract
Background: Systemic treatment has proven to improve physical symptoms in patients with advanced cancer.
Relationship between quality of life (QoL) or symptom burden (SYB) and treatment efficacy (tumour response and
survival) is poorly described. Therefore, we evaluated the predictive value of pretreatment QoL and SYB on treatment
outcomes.
Methods: Eligible patients had metastatic gastrointestinal cancers and were about to receive 1st/2nd line palliative
chemotherapy. 47 patients were consecutively enrolled. QoL and SYB were assessed by EORTC QLQ-C30 and MSKCC
MSAS questionnaires before treatment and after first response evaluation after 8–12 weeks. Logistic regression analysis
of QoL and SYB for prediction of objective treatment efficacy was performed. Patients were categorized according to
response rate (RR) based on RECIST1.1 and progression free survival (PFS). PFS was categorized by a ratio (individual
PFS/expected PFS) in above median (ratio ≥ 1) or below median PFS (ratio < 1). QoL and SYB were analysed for RR
groups (partial response, stable or progressive disease) and PFS ratio (PFSR).
Results: Objective response to chemotherapy and increase in PFS were associated with better pretreatment QoL and
less SYB. Patients with future objective treatment efficacy (PFSR≥ 1) evidenced clinically relevant better role/emotional/
cognitive/social functioning and less fatigue and appetite loss at baseline in comparison to PFSR < 1 (>10 points
difference). Lowest scores in all functioning scales at treatment start were seen in patients with future PFSR < 1. Global
health status (EORTC), PSYCH subscale and global distress index (MSAS) predicted PFSR, even if adjusted for gender,
age, cancer type, ECOG and line of treatment (p < 0.05). Interestingly, improved QoL and SYB (subjective benefit) were
noted even in patients with worse pretreatment status and no objective tumour response.
Conclusion: Future non-responders seem to show distinct QoL patterns before chemotherapy. This may facilitate early
detection of patients deriving less or even no benefit from treatment regarding prolongation of survival. Even in
patients with primarily progressive disease QoL and SYB may improve during treatment. Integration of QoL and
SYB assessment into decision-making about palliative chemotherapy seem to be an important approach to improve
patient outcome and should be further evaluated.
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Gastrointestinal cancers are among the most prevalent
causes of tumour-related deaths worldwide [1, 2]. Disease
management in the palliative setting has dramatically
improved throughout the last decade with the imple-
mentation of individualized and multimodal treatment
approaches and a large number of new licensed drugs
and integrated treatment modalities [3–9]. Moreover,
predictive molecular markers (e.g. RAS mutational status
in metastatic colorectal cancer) enable improved patient
allocation [10]. However, despite the current develop-
ments, the majority of patients will receive palliative treat-
ment in order to improve or delay symptoms and prolong
overall survival. Despite using patient and tumour related
factors (e.g. co-morbidity, age, histology) for treatment
selection, a substantial proportion of patients will not
derive a relevant benefit from palliative systemic treatment.
Identifying these patients before or at least early during
palliative chemotherapy is of utmost importance.
Currently, several scores are available to determine
individual prognosis of patients based on upfront bio-
chemical markers and performance status [11–14]. Al-
though prognostic and predictive variables differ between
tumour entities, performance status and/or age are in-
cluded in the majority of scores. However, performance
status according to Eastern Cooperative Oncology Group
(ECOG) is a mix of tumour related symptom burden and
patient related pre-”cancer” co-morbidity and/or frailty
and does not allow precise evaluation of reasons for future
non-response to treatment.
Quality of life (QoL) and symptom burden (SYB) can
be easily assessed by standardized self-administered ques-
tionnaires like the European Organisation for Research
and Treatment of Cancer Quality of Life Questionnaire
(EORTC QLQ-C30) or the Memorial Sloan Kettering
Cancer Center Symptom Assessment Scale (MSKCC
MSAS) and give a more specific overview of the current pa-
tient status. Likely, QoL and SYB have an influence on the
course of disease and potentially on treatment efficacy. Al-
though assessment of QoL has been commonly applied in
current trials, only little is known so far about the impact of
QoL and SYB prior to chemotherapy on treatment efficacy
defined by key oncological trial parameters such as re-
sponse rate (RR) or progression free survival (PFS) [15–17].
The purpose of this study was to investigate the influ-
ence of QoL and SYB prior to chemotherapy on treatment
efficacy (RR and PFS) determined by radiological as-
sessment (adjusted for established prognostic factors, e.g.
performance status (PS) and age). This exploratory trial
was designed to answer the following questions:
1. Do QoL and SYB prior to chemotherapy predict
treatment efficacy in terms of RR and PFS and do
they allow the identification of future non-responders?2. How do QoL and SYB change during chemotherapy
considering the achieved tumour response?
Given the exploratory and descriptive nature of these ques-
tions, no formal statistical assumptions were determined. To
evaluate the predictors among patients‘ QoL and SYB for
treatment efficacy we used logistic regression models.
Methods
Patient selection
Patients were eligible if standard (in terms of intensity
and dosing) first- or second-line palliative chemotherapy
for histologically confirmed metastatic gastrointestinal
cancer was scheduled. The applied (standard) regimens
are recorded in Table 1. The follow-up assessment had
to take place after first response evaluation after 8–12
weeks. To avoid selection bias patients were consecu-
tively recruited. Participants had to be able to complete
a battery of self-administered questionnaires. Minimum
age was 18 years. All patients provided written informed
consent before study entry according to institutional reg-
ulations. The ethical review committee of the medical
association of Hamburg had approved the trial.
Patients were consecutively recruited in the outpatient
clinic of the Department of Oncology, Hematology and
Bone Marrow Transplantation, University Medical
Center Hamburg-Eppendorf during daily routine of
chemotherapy visits from April 2012 to August 2013.
Assessments
QoL and SYB were assessed at two time points: at the
beginning of any new first- or second-line chemotherapy
and after the discussion of the first radiographic evalu-
ation of tumour response (usually performed after 8–12
weeks after the first cycles’ beginning onwards).
The patients’ performance status at time of trial inclu-
sion were graded according to ECOG performance status
[18]. Furthermore, the following baseline demographics
were assessed: age, gender, participation period, and line
of treatment. Tumour measurements using either com-
puted tomography (CT) or magnetic resonance imaging
(MRI) of all tumour lesions were performed to evaluate
RR (according to RECIST version 1.1) as well as PFS [19].
In order to assess potential influence of dose modifica-
tions on treatment efficacy these data were obtained at the
first radiographic evaluation.
To evaluate QoL and SYB, we used the standardized
and well-established EORTC QLQ-C30 as well as the
validated Memorial symptom assessment scale (MSKCC
MSAS) [20, 21].
Objective treatment efficacy
Objective treatment efficacy was evaluated according to
response criteria in solid tumours (RECIST) version 1.1.
Table 1 Expected progression free survival and applied regimen in the current study
1st line chemotherapy 2nd line chemotherapy
Cancer site Regimen (reference) Expected PFS
[months]
Regimen (reference) Expected PFS
[months]
Colon/rectum FOLFOX + bevacizumab or cetuximab [34, 35] 9 FOLFIRI+/− panitumumab or
bevacizumab [36–38]
5
Pancreas Gemcitabine based [39, 40] 4 fluoropyridimine +/− oxaliplatin [41] 2
Stomach/esophagus fluoropyrimidine/platinum +/− trastuzumab
for HER2 positive [42–44]
6 taxane or irinotecan [45] 3
Anal 5FU/platinum [46] 6 - -
Cholangiocarcinoma Gemcitabine +/− Cisplatin [47] 6 - -
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between partial response (PR), progressive disease (PD),
and stable disease (SD).
Furthermore, PFS (in months) was defined as the time
period between start of chemotherapy and either disease
progression according to RECIST v1.1 or death. All scores
were calculated at baseline and follow-up according to a
PFS ratio (PFSR) categorizing patients into those achieving
an expected or above median PFS for their respective dis-
ease and treatment line (PFSR ≥ 1) and patients with a
below median PFS (PFSR < 1). The ratio was determined
by the individual “achieved” PFS divided by the “expected”
PFS. The “expected” PFS values were derived from the
available literature taking into account current clinical tri-
als and are displayed in Table 1.
EORTC QLQ-C30
The EORTC Quality of Life Questionnaire (EORTC QLQ-
C30) was used to assess health-related quality of life and
was evaluated by following the procedures suggested in
the Scoring Manual [22, 23]. This questionnaire is com-
posed of five functioning scales (physical, social, role,
cognitive, and emotional functioning), a scale for global
quality of life, three 3-symptom scales (fatigue, nausea
and vomiting, and pain), and a number of single items
assessing additional symptoms (dyspnea, insomnia, appe-
tite loss, constipation, diarrhea, and financial difficulties).
All scales and single-item measures are linearly trans-
formed to scores from 0 to 100. On the function scales
and global quality of life scale, a score of 100 represents
maximum functioning, whereas on the symptom scales
and single items, a score of 100 indicates the worst pos-
sible symptoms. The interpretation of the patient groups’
mean values of the EORTC QLQ-C30 was performed re-
garding the previously reported threshold of a 10-point
difference as clinically relevant [24].
MSKCC-MSAS
The MSKCC-MSAS [25] assesses the prevalence, severity,
and distress of 32 symptoms experienced during the prior
week. Symptom prevalence and severity are measured on afour-point Likert scale. The prevalence is classified as
“rarely“, “occasionally“, “frequently“and “almost constantly“.
Symptom severity is defined as “slight“, “moderate“, “se-
vere“ and “very severe“.
Distress caused by a symptom is measured on a five
point Likert scale ranging from “not at all“ to “very much“
(in-between: “a little bit“, “somewhat“, “quite a bit“).
The questionnaire’s evaluation was performed based on
the authors’ guidelines [25].
Following these guidelines, a score was calculated for
each symptom and different symptom scores were com-
bined to calculate different subscale scores: PSYCH-subscale
(feeling sad, worrying, feeling irritable, feeling nervous,
difficulty sleeping and difficulty concentrating), PHYS-
subscale (lack of appetite, lack of energy, pain, feeling
drowsy, constipation, dry mouth, nausea, vomiting, change
in taste, weight loss, feeling bloated and dizziness), Global
Distress Index (GDI (feeling sad, worrying, feeling irritable,
feeling nervous, lack of appetite, lack of energy, pain,
feeling drowsy, constipation, dry mouth)) and MSAS total
score (all 32 symptom scores).
Statistical analysis
To evaluate potential predictors among patients’ QoL
and SYB prior to chemotherapy on future PFSR, logistic
regression models were used. Due to the likely influence
of variables like ECOG performance status, regression
analyses were adjusted for these parameters. Overall, 19
linear regression analyses for all QoL and SYB variables
were conducted, each one adjusted for gender, age, cancer
site, ECOG performance status and line of treatment. The
dependent variable was PFSR (PFSR ≥ 1 and PFSR < 1).
Significance was set at p = 0.05. Odds ratios (OR) are
presented with 95 % confidence limits (CI).
All statistical analyses were performed using SPSS 20
(IBM Corp.).
Results
Patient characteristics and treatment efficacy
Overall, 47 patients completed the first questionnaires of
whom 40 patients (85.1 %) completed the follow-up
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Table 2. Colorectal, pancreatic and gastric cancer were
the most frequent tumour types in this cohort.
PR according to the RECISTv1.1 was detected in 16
patients (34 %), SD in 22 (46.8 %), and PD in 9 patients
(19.2 %). According to the PFS ratio, 30 patients
(63.8 %) showed a PFS of the expected median or above
(PFSR ≥1), whereas 17 patients (36.2 %) showed a PFS
below the expected median (PFSR < 1).
Dose modifications occurred in overall 9 patients (3
treatment delays for a maximum of 8 days, 6 dose re-
ductions by a maximum of 25 % for all active agents).
However, treatment efficacy was similar in patients with
dose modifications (4 patients with PR, 3 with SD and 2
with PD).
Quality of life and symptom burden in relation to
objective treatment efficacy
Baseline and follow-up QoL and SYB mean values
were interpreted for PFSR and RR. The scores of the
baseline EORTC QLQ-C30 and MSKCC MSAS priorTable 2 Patients’ characteristics
Characteristics Total (%) n = 47 (100)





First-line chemotherapy 36 (76.6)












Partial Remission 16 (34)
Stable Disease 22 (46.8)
Progressive Disease 9 (19.2)
PFS-Ratio
≥ 1 30 (63.8)
< 1 17 (36.2)
Mean participation period in weeks (SD) 8.8 (3.5)to chemotherapy illustrated remarkable differences be-
tween patients with future responding and future non-
responding tumours. Patients with future treatment
efficacy (PFSR ≥ 1) had a clinically relevant better Qol/
GHS, role functioning (RF), emotional functioning (EF),
cognitive functioning (CF) and social functioning (SF) in
comparison to PFSR < 1 (>10 points). Lowest scores in all
functioning scales at treatment start were seen in patients
with future PFSR < 1 and PD. The GHS prior to chemo-
therapy had a significant impact (p = 0.006) on PFSR and
may be seen as a predictive parameter for treatment effi-
cacy (Table 3). Similar albeit non-significant results were
seen in the PR group compared to PD. Moreover, fewer
symptoms prior to chemotherapy may predict treatment
efficacy. With a difference of 10 points the PFSR ≥ 1 group
showed less fatigue and appetite loss, and with a difference
of 5 points less dyspnoea and financial problems. The
chance to belong to the PFSR < 1 group changes with a
one unit increase of GHS by the factor of 0.95. Thus, a 10
points higher score at baseline would be associated with a
change in the odds by the factor 0.61 (0.95 to the power of
10 = 0.61) (p = 0.006, OR = 0.95, 95 % CI 0.92-0.99).Table 3 Logistic regression analysis on baseline variables
Dependent variable: PFSR. Independent variables: EORTC and
MSKCC SAS variables adjusted for gender, age, cancer type,
ECOG performance status and line of treatment
Independent Variable p-value Regr. OR 95 %-CI for OR
min max
EORTC QLQ C30
Global Health Status 0.006 −0.050 0.951 0.918 0.986
Physical Functioning 0.465 −0.009 0.991 0.967 1.015
Role Functioning 0.360 −0.009 0.991 0.973 1.010
Emotional Functioning 0.130 −0.017 0.983 0.961 1.005
Cognitive Functioning 0.139 −0.025 0.976 0.944 1.008
Social Functioning 0.099 −0.016 0.984 0.965 1.003
Fatigue 0.219 0.014 1.014 0.992 1.037
Nausea and Vomiting 0.938 −0.001 0.999 0.972 1.027
Pain 0.962 0.001 1.001 0.980 1.022
Dyspnoea 0.851 0.002 1.002 0.984 1.019
Diarrhoea 0.109 −0.020 0.980 0.956 1.005
Insomnia 0.860 0.002 1.002 0.984 1.020
Appetite Loss 0.197 0.011 1.011 0.995 1.027
Constipation 0.331 −0.014 0.986 0.957 1.015
Financial Difficulties 0.214 0.012 1.012 0.993 1.032
MSKCC-MSAS
PSYCH-Subscale 0.032 0.896 2.450 1.081 5.556
PHYS-Subscale 0.283 0.514 1.671 0.654 4.272
GDI 0.014 1.120 3.064 1.256 7.475
Total Score 0.405 0.532 1.702 0.487 5.953
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ticularly in patients achieving disease control (PR and
SD). Interestingly, even in patients with no or decreased
impact on survival (PFSR < 1) mean GHS improved by
more than 10 points. The functioning scales showed no
remarkable changes at follow up assessment for PFSR ≥ 1,
whereas PFSR < 1 showed improved SF. RF deteriorated in
the PFSR < 1 group potentially reflecting patients’ limita-
tion in everyday life due to the harmful combination of
chemotherapy’s side effects and progressive tumour dis-
ease. Symptom scores as fatigue, pain and insomnia at
follow-up assessment remarkably deteriorated in the PD
group.
The GDI seems to have predictive value for treatment
efficacy in terms of PFSR (p = 0.014, OR = 3.064), even if
adjusted for age, gender, cancer site, line of treatment
and ECOG PS. Further more, the PSYCH-Subscale seems
to have a predictive value for the future response to
chemotherapy (p = 0.032, OR = 2.450). PHYS-Subscale
shows similar trends. Prior to chemotherapy, high mean
values and therefore poor physical and psychological
functioning (PHYS- and PSYCH Subscale) were seen in
the PD group as well as for PFSR < 1. During course of
chemotherapy, PHYS and PSYCH subscales indicated
improved symptom control and less psychological prob-
lems in all patients independent from RR or PFS. How-
ever, the improvement was pronounced in those patients
starting with worse QoL and SYB and deriving less benefit
in terms of survival (PFSR < 1). GDI and MSAS total score
at follow up showed similar changes. Interestingly, even
patients with PD showed this improvement of physical
and psychological symptoms in the MSAS.
Discussion
The current study evaluated the role of QoL and SYB at
baseline and the changes after the first response assessment
by CT or MRI in patients with metastatic gastrointestinal
cancer. Particularly the prediction of treatment efficacy
determined by key oncological parameters (tumour re-
sponse and PFS) and the alteration of QoL and SYB
after chemotherapy were assessed.
The results illustrate that patients who will achieve a
relevant tumour response or at least an expected PFS
(PR and PFSR ≥ 1) had a significantly better health status
(GHS), less psychological problems (PSYCH-Subscale) and
lower distress (GDI) prior to chemotherapy than patients
who progressed early. Therefore, GHS, PSYCH-Subscale
and GDI seem to have predictive value for treatment effi-
cacy. All other items of the applied questionnaires showed
a similar association of better QoL and SYB with increased
treatment efficacy (PR and PFSR ≥ 1). However, the num-
ber of patients was too small to show a significant associ-
ation for further single items or sub-scales with treatment
efficacy. Although the analyses were adjusted for ECOGperformance status and line of therapy these findings could
be influenced by disease burden and aggressiveness. Thus,
future studies should focus on single tumour types in prior
untreated patients including established scores determining
biology of disease and co-morbidity [11–14].
The patients with low QoL and high SYB prior to
chemotherapy seem to be at high risk not to radiograph-
ically respond to chemotherapy in comparison to patients
with moderate SYB and relatively good QoL. In particular,
suffering of physical symptoms (mainly fatigue and ap-
petite loss) prior to chemotherapy may indicate a lack
of future objective treatment efficacy. Interestingly, these
factors were among the main issues of relevance for
cancer patients in a recent survey [26]. The impact of
SYB before chemotherapy on treatment efficacy is well
known and reflected by the prognostic value of perform-
ance status on survival, which has therefore been integrated
in different scores in the last decades [11–14, 27–29].
Moreover, physical symptoms at baseline significantly
predicted treatment efficacy in metastatic gastrointestinal
cancer [12]. Relevant physical symptoms such as fatigue
and appetite loss may reveal an aggressive or advanced
disease prior to chemotherapy and could thus allow
the early detection of high-risk patients for future non-
response [30, 31].
Despite the severity of physical symptoms in patients
with a future non-responding tumour disease, several in-
teresting issues were noted regarding psychosocial fac-
tors. The future non-responding patients as compared to
the future responders were more limited in role- and
emotional functioning and had higher distress levels.
During the course of chemotherapy, stabilisation or
even improvement of the initial low QoL and high SYB
(subjective benefit) is of high relevance in a palliative set-
ting independent of objective tumour response or pro-
longation of survival. Interestingly, patients with worse
QoL and SYB at baseline as compared to those with mod-
erate scores seem to derive more subjective benefit from
palliative chemotherapy in terms of improvement of qual-
ity of life and symptom burden. This points towards a
beneficial impact of palliative chemotherapy even though
no objective tumour response or increase in survival is
achieved [32]. Of note, the current study did only evaluate
pretreatment QoL and SYB and 8–12 weeks thereafter.
Thus, long term effects, as the recently shown deleterious
effects of chemotherapy use on QoL at the end of life,
could not be analysed [33]. The noted short term subject-
ive benefit despite radiographical non-response in pa-
tients with worse pretreatment QoL and SYB might be
caused by at least some effect on tumour growth or by
the psychological effect of applying an active and po-
tentially effective treatment.
Some patients do not derive any benefit (subjective
or objective) at all by palliative chemotherapy. In the
Table 4 EORTC QLQ-C30 mean values at baseline and follow-up assessment of response rate and progression free survival-ratio
according to RECIST (PR = partial remission, SD = stable disease, PD = progressive disease, PFS = progression free survival ratio)
Response PFS
RECIST Baseline Follow-up Ratio Baseline Follow-up
QoL/GHS (Quality of Life/Global Health Status) PR 53.65 57.81 >1 59.17 56.85
SD 53.03 55.00
PD 41.67 36.11 <1 36.76 49.24
PF (Physical Functioning) PR 65.00 70.83 >1 68.22 69.20
SD 70.91 67.30
PD 57.04 48.89 <1 62.75 62.42
RF (Role Functioning) PR 57.29 48.96 >1 57.78 55.75
SD 57.58 54.76
PD 37.04 22.22 <1 46.08 34.85
EF (Emotional Functioning) PR 70.31 68.23 >1 65.00 66.96
SD 59.85 63.33
PD 43.52 55.56 <1 51.96 59.09
CF (Cognitive Functioning) PR 87.50 81.25 >1 88.33 83.33
SD 88.64 83.33
PD 68.52 72.22 <1 77.45 77.27
SF (Social Functioning) PR 39.58 51.04 >1 52.77 57.14
SD 56.06 64.17
PD 31.48 22.22 <1 33.33 51.52
FA (Fatigue, Symptom Score) PR 37.50 47.22 >1 44.44 43.68
SD 50.00 41.27
PD 62.96 74.07 <1 54.90 52.52
NV (Nausea and Vomiting, Symptom Score) PR 17.71 13.54 >1 16.67 14,94
SD 16.67 15.08
PD 16.67 5.56 <1 17.65 10.61
PAIN (Symptom Score) PR 29.17 30.21 >1 26.67 21.83
SD 21.97 15,87
PD 35.19 50.00 <1 27.45 30,30
DYS (Dyspnoe, Symptom Score) PR 20.83 31.25 >1 33.33 37.93
SD 39.39 44.44
PD 51.85 55.56 <1 39.22 45.45
INS (Insomnia, Symptom Score) PR 27.08 22.92 >1 37.78 28.74
SD 50.00 39.68
PD 33.33 44.44 <1 41.18 45.45
AL (Appetite Loss, Symptom Score) PR 31.25 33.33 >1 32.22 34.48
SD 31.82 28.57
PD 62.96 44.44 <1 47.06 24.24
CON (Constipation, Symptom Score) PR 14.58 6.25 >1 14.44 9.52
SD 9.09 11.67
PD 12.50 0.00 <1 6.25 6.06
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Table 4 EORTC QLQ-C30 mean values at baseline and follow-up assessment of response rate and progression free survival-ratio
according to RECIST (PR = partial remission, SD = stable disease, PD = progressive disease, PFS = progression free survival ratio)
(Continued)
DIA (Diarrhoea, Symptom Score) PR 18.75 27.08 >1 28.89 29.76
SD 27.27 26.67
PD 29.63 33.33 <1 17.65 21.21
FIN (Financial Difficulties, Symptom Score) PR 29.17 27.03 >1 22,22 27.16
SD 24.24 35.09
PD 18.52 0.00 <1 29.41 33.33
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follow up pain, fatigue and insomnia increased accom-
panied by remarkable deteriorations of SF, RF and
GHS during chemotherapy. Premature stop of chemo-
therapy and initiation of palliative care would likely
improve QoL and SYB in this patient group. Although,
QoL and SYB prior to chemotherapy seem to predict
objective treatment efficacy in terms of RR and PFS,
stratification of patients deriving subjective benefit
(defined as improvement of QoL and SYB) is difficult.
Further research is needed to potentially define a cut
off value of a composite of several QoL and SYB items
or subscores to upfront identify patients with a detri-
mental impact of palliative chemotherapy. The current
study underlines the potential utility of integrating pa-
tient reported measures into decision-making about
palliative chemotherapy.
This study has several limitations. Incomplete follow-up
data pose a problem, single centre evaluation as a well as
the small sample size. Seven patients were lost to follow-
up due to progressive disease or death. However, based on
the above mentioned findings inclusion of more patients
would probably have enhanced the findings, but notTable 5 MSKCC-MSAS mean values at baseline and follow-up assessm
to RECIST (PR = partial remission, SD = stable disease, PD = progressive
Response
CT-scan Baseline
PSYCH (Subscale MSAS) PR 0.93
SD 1.10
PD 1.57
PHYS (Subscale MSAS) PR 0.99
SD 0.90
PD 1.34
GDI (Global Distress Index, MSAS) PR 1.24
SD 1.42
PD 2.03
Total Score MSAS PR 0.78
SD 0.84
PD 1.15relevantly changed them. With the inclusion of different
tumour types and first as well as second line patients the
population is rather heterogeneous. Therefore, the logistic
regression analyses were adjusted for gender, age, cancer
type, line of treatment and in particular ECOG perform-
ance status. Patients were recruited consecutively, thus se-
lection bias was minimized. Patients’ selection was based
on a scheduled standard chemotherapy for the respective
disease setting in terms of intensity and dosing. Therefore,
patients scheduled for upfront dose reduction or single
agent treatment due to reduced general health status were
not eligible. In order to assess the potential influences of
dose modifications on treatment efficacy these data were
obtained at the follow up imaging, showing no relevant
correlation. To be able to set the PFS data obtained in the
heterogeneous study population into context, the PFS ra-
tio was chosen for further analyses. The expected PFS data
are derived from patient populations included into clinical
trials with inclusion criteria differing from our patient
population in some aspects (e.g. ECOG mainly limited
to ≤1), whereas particularly the median age was in the
range of the trial selection criteria. This study was a pilot
study to generate hypotheses to be prospectively tested inent of response rate and progression free survival ratio according
disease, PFS = progression free survival)
PFS
Follow-up Ratio Baseline Follow-up
0.86 >1 0.95 0.87
0.97
1.27 <1 1.47 1.14
1.03 >1 0.92 0.96
0.84
1.14 <1 1.19 0.89
1.21 >1 1.24 1.23
1.30
1.98 <1 1.89 1.52
0.85 >1 0.81 0.87
0.85
0.96 <1 1.00 0.83
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trials in better defined patient populations with specific
survival data. In consideration of testing multiple hy-
potheses results should be interpreted with caution. Interest-
ingly, the global scores were significantly altered, whereas
most single items showed strong trends. This distribution
points to clinically relevant and reliable results. Nevertheless
further research is urgently warranted focusing on distinct
disease entities and settings in larger groups of patients.
Conclusion
In cancer patients, physical and mental condition will
influence the impact of palliative chemotherapy on ob-
jective (RECIST) and subjective (alleviation of quality of
life and symptoms) treatment efficacy. A good quality of
life, less psychological problems and lower distress are
suggested to be positive predictors for treatment efficacy
in terms of objective tumour response and survival. In
contrast, subjective benefit could be achieved even in
patients with low quality of life and high symptom bur-
den prior to chemotherapy. Although further research
is needed to better define patients’ subgroups, integration
of QoL and SYB assessments into individualized decision-
making in the palliative setting seems to be of high
relevance.
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